[Form 4] Huron Consulting Group Inc. Insider Trading Activity
Rhea-AI Filing Summary
James H. Roth, a director of Huron Consulting Group Inc. (HURN), reported two open-market sales on 09/02/2025 totaling 2,000 shares executed pursuant to a Rule 10b5-1 trading plan. The sales were reported as 506 shares at a weighted average price of $136.99 and 1,494 shares at a weighted average price of $137.68, reflecting transaction price ranges detailed in the filing. After these transactions Mr. Roth beneficially owned 41,304 shares directly and 3,855 shares indirectly through a family LLC. The Form 4 was signed by an attorney-in-fact and includes an undertaking to provide detailed per-price sale information on request.
Positive
- Sales executed under a Rule 10b5-1 plan, reducing likelihood of timing-based inference
- Filing discloses weighted-average prices and price ranges and offers to provide per-price details on request
- Clear post-transaction ownership disclosure showing direct and indirect holdings
Negative
- Insider sold 2,000 shares, which may be viewed negatively by some investors as insider liquidity
- Sale reduces direct holdings from previously higher levels to 41,304 shares (direct)
Insights
TL;DR: Director sold a small portion of holdings under a 10b5-1 plan; transactions are routine insider liquidity, not a material corporate event.
The reported sale of 2,000 shares on 09/02/2025 was executed under a pre-established Rule 10b5-1 plan, which reduces timing-based inference about intent. Sale prices (weighted averages $136.99 and $137.68) and the aggregate size relative to reported post-sale holdings (41,304 direct shares) indicate this is modest insider disposition rather than a control change or large divestiture. Disclosure includes an undertaking to provide per-price detail, supporting transparency. No derivatives or other compensatory transactions were reported.
TL;DR: Reporting follows Section 16 requirements and notes use of a 10b5-1 plan, demonstrating procedural compliance.
The Form 4 clearly identifies the reporting person as a director and marks the sales as pursuant to a written 10b5-1 plan adopted May 8, 2025, which provides an affirmative defense under Rule 10b5-1(c). The filing is signed by an attorney-in-fact and includes explanatory footnotes about price ranges. From a governance perspective, documentation and willingness to supply detailed per-price sale information on request are positive compliance signals. There are no indications of contemporaneous related-party or derivative transactions in this filing.